Diabetes

 
Guideline Topline: 14 Key Lifestyle Interventions to Treat, Prevent Type 2 Diabetes
June 12, 2025

These 14 recommendations from the American College of Lifestyle Medicine comprise the core of the first-ever guideline centered on lifestyle change as a first-line intervention.

High Discontinuation Rates of GLP-1 RA-Based Drugs Linked to Weight Loss Far Below Phase 3 Clinical Trials
June 12, 2025

High discontinuation rates as well as lower maintenance dosages of semaglutide and tirzepatide were among the independent predictors of lower real-world weight loss.

First-Ever Guideline Establishes Lifestyle Intervention as Central Strategy in Treating, Reversing Type 2 Diabetes and Prediabetes
June 11, 2025

Novel guidelines include specific strategies that support the prescription, implementation, and monitoring of lifestyle changes to reach glycemic control and, possibly, disease remission.

New-Onset T2D Tied to Higher Risk of Obesity-Related Cancer: Daily Dose
June 03, 2025

Your daily dose of the clinical news you may have missed.

Coexisting Hypertension and Type 2 Diabetes in US Adults Doubled Over 2 Decades: New Study
May 30, 2025

Adults with both HTN and T2D had more than twice the risk of all-cause mortality and nearly three times the risk of cardiovascular mortality, according to new data.

ASCO 2025: GLP-1 Receptor Agonists Linked to Modest Reduction in Obesity-Related Cancer Risk
May 28, 2025

GLP-1 receptor agonists showed promise in lowering obesity-related cancer risks in adults with type 2 diabetes, particularly colorectal cancer.

Investigational GPR119 Agonist Shows Dual Hepatoprotective and Glycemic Benefits in MASH Patients
May 07, 2025

EASL 2025. DA-1241 significantly reduced plasma ALT levels, improved systemic inflammatory and fibrosis biomarkers, according to drug developer MetaVia.

Tirzepatide Switch Outperforms Dulaglutide Dose Escalation in T2D: Daily Dose
May 05, 2025

Your daily dose of the clinical news you may have missed.

Adolescent Hyperglycemia, Insulin Resistance Drive Early Cardiac Structural Changes, Novel Cohort Study Finds
May 02, 2025

Persistent hyperglycemia between ages 17 and 24 tripled the risk of left ventricular hypertrophy and did so 5 times faster among young women, a new study found.

Oral Semaglutide Cuts MACE Risk by 14% in High-Risk Adults: Daily Dose
April 25, 2025

Your daily dose of the clinical news you may have missed.